Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 Combined With Docetaxel in mCRPC Post-Abiraterone
NCT04603833Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04603833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603833.